RedHill Biopharma Announces QIDP FastTrack Designation Granted by FDA to RHB104 for Nontuberculous Mycobacteria Infections

RHB104 has been granted Qualified Infectious Disease Product QIDP designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria NTM InfectionÂÂ Â Under FDA's Generating Antibiotic Incentives Now GAIN Act QIDP designation allow...